Nucleic Acid Construct for Stable Bioluminescence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bioluminescent systems for cellular monitoring are limited by requiring expensive externally applied reagents, being restricted to single time points, and failing to function at temperatures relevant for most applications, hindering their use in drug development, toxicology, and environmental monitoring.
Innovation Solution
A nucleic acid construct encoding multiple genes of a luciferin/luciferase pathway, including protease recognition sites and viral 2A peptides, is used to create a thermostable bioluminescent system that allows continuous and autonomous bioluminescent production in cells at various temperatures without exogenous stimulators.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If externally applied reagents are used for bioluminescence, then bioluminescent detection can be achieved, but the system requires expensive reagents and is limited to single time points
Solution Approach 1:
The patent implements self-service by engineering cells to autonomously produce all components of the bioluminescence pathway. The nucleic acid construct encodes multiple genes including luciferase and luciferin pathway enzymes, allowing the cell to generate bioluminescence signals without external reagent addition. This eliminates the need for expensive externally applied reagents while enabling continuous monitoring across multiple time points.
2Ease of operation
If bioluminescent genes are expressed in cell lines, then cellular monitoring is enabled, but stable continuous expression at relevant temperatures cannot be achieved
Solution Approach 1:
The patent applies parameter changes by optimizing the nucleic acid construct for thermal stability at physiological temperatures. The construct includes specific promoter elements, gene sequences, and regulatory regions that maintain stable transcription and translation of bioluminescence pathway genes at 37°C and other relevant temperatures. This enables continuous autonomous bioluminescence production without temperature-dependent expression instability.
3Extent of automation
If multiple genes of the luciferin/luciferase pathway are co-expressed, then autonomous bioluminescence is achieved, but the complexity of the nucleic acid construct increases
Solution Approach 1:
The patent merges multiple genes of the luciferin/luciferase pathway into a single integrated nucleic acid construct. The construct co-expresses luciferase, luciferin pathway enzymes, and regulatory elements in a unified transcriptional unit. This combining approach enables autonomous bioluminescence production while managing construct complexity through coordinated expression from a single genetic element rather than multiple separate transgenes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables stable, continuous, and autonomous bioluminescent production in cells, facilitating real-time, non-invasive monitoring of cellular processes over prolonged periods, improving the utility of bioluminescence in research and monitoring applications.
Implementation Method 1
Bioluminescence, the production of light from a living cell, would be an ideal detection modality for these applications
Implementation Method 2
a first protease recognition nucleic acid sequence encoding a protease recognition site
Data Source
AI summary
A system for stable expression of gene pathways in cell lines, methods of making cell lines with stable expression of gene pathways, and methods of using the same are disclosed herein. The system comprises a nucleic acid construct configured to encode at least two genes of a multigene pathway in a cell. The nucleic acid construct comprises a plurality of nucleic acid sequences, wherein the plurality of nucleic acid sequences comprises: a first nucleic acid sequence encoding at least one gene of the multigene pathway; a first protease recognition nucleic acid sequence encoding a protease recognition site; a first linker nucleic acid sequence encoding a linker region, wherein the linker region comprises a viral 2A peptide; and a second nucleic acid sequence encoding at least one gene of the multigene pathway.